These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 20515495)

  • 1. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.
    Krakstad C; Chekenya M
    Mol Cancer; 2010 Jun; 9():135. PubMed ID: 20515495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
    Chen L; Liu YC; Zheng YY; Xu J; Zhang Y; Liu WL; Li ZY; Huang GD; Li WP
    Phytother Res; 2019 Jun; 33(6):1736-1747. PubMed ID: 31006910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
    Taylor TE; Furnari FB; Cavenee WK
    Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeting of glioblastoma: Drug discovery and therapies.
    Bai RY; Staedtke V; Riggins GJ
    Trends Mol Med; 2011 Jun; 17(6):301-312. PubMed ID: 21411370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanisms of Drug Resistance in Glioblastoma.
    Dymova MA; Kuligina EV; Richter VA
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
    Custodio A; Calles A; Pérez-Segura P
    Clin Transl Oncol; 2010 Apr; 12(4):310-4. PubMed ID: 20462843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the AKT pathway in glioblastoma.
    McDowell KA; Riggins GJ; Gallia GL
    Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive activation of Notch2 signalling confers chemoresistance to neural stem cells via transactivation of fibroblast growth factor receptor-1.
    Tomé M; Tchorz J; Gassmann M; Bettler B
    Stem Cell Res; 2019 Mar; 35():101390. PubMed ID: 30763736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
    Reardon DA; Wen PY
    Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
    Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
    J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiproliferative and apoptotic effects of apigenin on glioblastoma cells.
    Stump TA; Santee BN; Williams LP; Kunze RA; Heinze CE; Huseman ED; Gryka RJ; Simpson DS; Amos S
    J Pharm Pharmacol; 2017 Jul; 69(7):907-916. PubMed ID: 28349530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine.
    Zhao Z; Liu Y; He H; Chen X; Chen J; Lu YC
    Brain Res Bull; 2011 Oct; 86(3-4):189-94. PubMed ID: 21807073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance.
    Ding Z; Kloss JM; Tuncali S; Tran NL; Loftus JC
    Neoplasia; 2020 Sep; 22(9):352-364. PubMed ID: 32629176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 as a Therapeutic Target for Glioblastoma.
    Liu Y; Li C; Lin J
    Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.